Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB) (Q57095808)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

title

Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

multidrug-resistant tuberculosis

13 April 2020

main subject

multiple drug resistance

1 reference

1 reference

1 reference

Yongge Liu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Makoto Matsumoto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Hidekaza Ishida

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Kinue Ohguro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Masuhiro Yoshitake

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Rajesh Gupta

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Lawrence Geiter

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Jeffrey Hafkin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

language of work or name

English

0 references

publication date

3 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

page(s)

20-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

13 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Tuberculosis, drug resistance, and the history of modern medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Metabolic Mechanism of Delamanid, a New Anti-Tuberculosis Drug, in Human Plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Erratum for Sasabe et al., Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid is not metabolized by Salmonella or human nitroreductases: A possible mechanism for the lack of mutagenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Nitroimidazoles for the treatment of TB: past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid for multidrug-resistant pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid for Extensively Drug-Resistant Tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Six-Month Response to Delamanid Treatment in MDR TB Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

Metabolic engineering of cofactor F420 production in Mycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2018.04.008

10.1016/J.TUBE.2018.04.008

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30029909%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

1 reference